Vietnamese, Israeli firms to sign cooperation agreement on oral COVID-19 vaccine
Viet Nam’s Tan Thanh Holdings and 10 Pharma JSC will be distributors of COVID-19 vaccine Oravax throughout Southeast Asian nations, comprising Viet Nam, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore and Thailand.
Latest
 |
| At the signing ceremony for cooperation agreement of oral COVID-19 vaccine Oravax. (Photo: Tuan Anh) |
Oravax Medical of Israel's Oramed Pharmaceuticals and the Vietnamese firms signed the cooperation agreement of oral COVID-19 vaccine Oravax at a ceremony held online on December 29.
Nadav Kidron, Chief Executive of Oramed and Oravax Chairman, said the deal, worth hundreds of millions of US dollars for Oravax, includes pre-order of oral vaccine.
He viewed Tan Thanh Holdings as an ideal partner for his business to bring the oral vaccine to Viet Nam and other ASEAN member countries that have a combined population of over 660 million.
"The partnership agreement, which includes the pre-purchase of Oravax's oral COVID-19 vaccine, marks an important milestone for Oravax Medical. The oral COVID-19 vaccine will significantly improve the logistics of vaccination and reduce costs, compared to the complex infrastructure requirements of current injectable vaccines and is expected to help minimize unwanted side effects," said Nadav Kidron.
Addressing the signing ceremony, Vietnamese Ambassador to Israel Do Minh Hung stressed the significance of the cooperation, saying this is the first time Viet Nam and Israel have cooperated in high-tech health care, both in terms of trade and technology transfer.
The cooperation contents match guidelines of the Vietnamese Government and meet domestic demand for vaccine access, he said.
| Information about Oravax Oral Vaccine: Oravax's oral VLP vaccine targets three surface proteins of the SARS CoV-2 virus, including proteins that are less sensitive to mutations, thus making it potentially more effective against current and future variants of the COVID-19 virus. In addition, Oravax's VLP vaccine technology is highly scalable for manufacturing and can be easily transferred for large-scale distribution in terms of logistics, as no cryopreservation is required. This technology is the research result of Professor Avram Hershko - Israeli biochemist, winner of the 2004 Nobel Prize in Chemistry and developed in preclinical trials by Oramed Pharmaceuticals. Oravax is currently in phase 1 clinical trial in South Africa. |
